Sermorelin Powder

Palatin Technologies Inc. (NYSE: PT-141) announced today that it has shown positive results in a Phase I clinical trial of pT-141 for the treatment of sexual dysfunction in normal premenopausal women. The trial included 32 healthy female volunteers and evaluated their response to pT-141 and placebo in response to visual stimuli. Pt-141 was found to be safe and resulted in a significantly greater improvement in vaginal blood flow than placebo users (P< 0.05). role Such antibiotics first affect the outer membrane of sensitive bacteria. Drug ring part of polypeptide amino and lipopolysaccharide in the outer membrane 2 valence cations combining site to produce electrostatic interaction, destroy the integrity of the outer membrane damage